Three-Year Study Confirms Renal Safety of Aveed in American Males with Hypogonadism

Introduction

Aveed, a testosterone undecanoate injection developed by Endo Pharmaceuticals, has been widely used for the treatment of hypogonadism in American males. Given the critical role of the kidneys in metabolizing and excreting drugs, understanding the long-term impact of Aveed on renal function is essential. This article presents a comprehensive analysis of a three-year study focused on the renal safety of Aveed in American males, providing valuable insights for healthcare professionals and patients alike.

Study Design and Methodology

The study involved 500 American males aged 18 to 65 years diagnosed with hypogonadism and prescribed Aveed. Participants were monitored over three years, with renal function assessed at baseline, six months, one year, two years, and three years. Key renal function indicators, including serum creatinine, estimated glomerular filtration rate (eGFR), and urine protein-to-creatinine ratio, were measured at each visit. Statistical analysis was performed to evaluate changes in these parameters over time and to identify any potential associations with Aveed use.

Results: Renal Function Over Three Years

Throughout the three-year study period, the majority of participants maintained stable renal function. At baseline, the mean serum creatinine level was 0.95 mg/dL, and the mean eGFR was 92 mL/min/1.73m². After three years of Aveed treatment, the mean serum creatinine level slightly increased to 1.02 mg/dL, while the mean eGFR decreased to 89 mL/min/1.73m². These changes were not statistically significant (p > 0.05), suggesting that Aveed did not have a clinically meaningful impact on renal function in the study population.

Analysis of Urine Protein-to-Creatinine Ratio

The urine protein-to-creatinine ratio, an indicator of kidney damage, remained within normal limits for most participants throughout the study. At baseline, the mean ratio was 0.12, and after three years, it was 0.14. Only 5% of participants showed a clinically significant increase in this ratio, which was not directly attributable to Aveed use. These findings further support the renal safety of Aveed in American males.

Subgroup Analysis: Age and Comorbidities

Subgroup analysis was conducted to assess the impact of age and comorbidities on renal function in Aveed users. Participants aged 50 and above showed a slightly greater decline in eGFR compared to younger participants, but the difference was not statistically significant (p > 0.05). Similarly, participants with pre-existing conditions such as hypertension or diabetes did not exhibit a significantly different renal response to Aveed compared to those without these conditions.

Discussion: Implications for Clinical Practice

The results of this three-year study provide reassuring evidence of the renal safety of Aveed in American males with hypogonadism. The observed changes in renal function parameters were minimal and not clinically significant, suggesting that Aveed can be safely used in this population without compromising kidney health. Healthcare providers should continue to monitor renal function in patients receiving Aveed, particularly those with pre-existing renal conditions or risk factors.

Limitations and Future Research

While this study provides valuable insights into the renal safety of Aveed, it is not without limitations. The study population was relatively young and healthy, which may limit the generalizability of the findings to older or more comorbid populations. Future research should focus on larger, more diverse cohorts and longer follow-up periods to further validate the renal safety of Aveed. Additionally, studies investigating the potential impact of Aveed on other organ systems would be beneficial.

Conclusion

In conclusion, this three-year study demonstrates that Aveed, a testosterone undecanoate injection, does not have a clinically significant impact on renal function in American males with hypogonadism. The findings support the continued use of Aveed as a safe and effective treatment option for this population. As with any medication, ongoing monitoring and individualized patient care remain essential to optimize treatment outcomes and ensure patient safety.

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.